|
Schirdewan博士的引述的參考文獻:
! s. G6 @& I" V. X3 w' `8 [0 b S, s0 R X8 M: d7 ~$ C ^. ]. V) ]1 M, X
Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009.
# f! P+ ~5 g& y& ]' |% E5 W
5 \7 q0 j5 }8 _0 X: v: \& jDaubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008
& H# @1 M! W5 K l' ? u
' R4 u, ^ b% t! Q& PRicci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010.
Q9 s" N0 {9 ?, t
7 X* {% H3 C J( N關於BIOTRONIK SE & Co. KG' Y% R( T( ^! V2 w! ~
7 O( Z8 j* H+ P! o. @BIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|